Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

Components of
Meningococcal Vaccine

Excipients Table
Allergens Table
Components Table

 

Indication

Active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup A, C, Y, and W-135       

Proprietary Name

Menactra

MENOMUNE-A/C/Y/W-135

Menveo

Manufacturers

sanofi pasteur

sanofi pasteur

Novartis

Viability

Inactivated

Inactivated

Inactivated

Approved Ages 9 mos - 55 years 2 years and older 2-55 years

Microorganism

Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens

Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y and Group W-135

Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

Dose

0.5 mL

0.5 mL

0.5mL

Route

Intramuscular

Subcutaneous

Intramuscular

Dose form

Liquid

Freeze-dried preparation

Liquid

Appearance

Clear to slightly turbid liquid.

Clear, colorless liquid

Clear, colorless liquid

Concentration (per 0.5 mL)

Meningococcal A, C, Y, - 4 mcg each

W-135 polysaccharides, 4 mcg 

Diphtheria toxoid protein carrier, 48 mcg

 “Isolated product” from each of Groups A, C, Y and W-135 in an isotonic sodium chloride solution, 50 mcg each

MenA oligosaccharide, 10 mcg

MenC, MenY and MenW-135 oligosaccharides,5 mcg of each

CRM197 protein, 32.7 to 64.1 mcg 

Preservatives

None

None in single dose vial

Thimerosal, 25 mcg  multidose vial 

None

Adjuvants

None

None

None

Excipients

Sodium phosphate buffered isotonic sodium chloride solution

Lactose, 2.5 to 5 mg

Formaldehyde, residual

CY medium containing yeast extracts and amino acids

Allergens

Stopper of the vial contains dry natural rubber latex

Stopper of the vial contains dry natural rubber latex 

 

Media

Cultured on Mueller Hinton agar and grown in Watson Scherp media

Casamino acid medium and medium 199. N. Meningitidis are cultivated with Mueller Hinton agar1 and Watson Scherp2 media

Franz Complete medium and treated with formaldehyde

Packaging

Vial, single dose and 5 single-dose package

Vial, single dose + diluent

5 single dose + diluent packs

10-dose vial + dilent (not to be used with jet injector)

Vial of MenA lyophilized conjugate component and a vial of MenCYW-135 liquid conjugate component (1 dose after reconstitution). 5 doses (10 vials) per pack

Routine Storage

2 to 8° C (35-46° F)

Do not freeze

2 to 8° C (35-46° F)

Do not freeze

2 to 8° C (35-46° F)

Do not freeze

PI Last updated November 2011 May 2012 March 2011

updated September 2012

This page was last updated on February 12, 2014

© 2014 Institute for Vaccine Safety